Captozyme, Inc. announced today that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet.
After working with the Burdock Group to recently obtain a successful self-contained GRAS (Generally Recognized As Safe) determination for its oxalate-reducing enzyme, biotechnology company Captozyme licensed the rights for commercialization to Entring LLC, which will make it available for purchase this fall as a food ingredient. Consumers seeking a low-oxalate diet can add the virtually tasteless, odorless powder to a variety of oxalate-packed foods and beverages to help reduce the presence of the anti-nutrient.
Helena Cowley, CEO of Captozyme, which was named a GrowFL Company To Watch in 2017, was the company's first employee. She never set out to be an entrepreneur, but says the process of growing the company has certainly turned her into one.
Captozyme, a Gainesville-based biotechnology company, is among 50 statewide companies expected to see significant growth over the next several years. Captozyme was selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association with the Edward Lowe Foundation.
Nephure™, an oxalate degrading enzyme manufactured by Captozyme, has received self-affirmed GRAS (Generally Recognized as Safe) notification by an independent panel of experts through scientific procedure following stringent US Food and Drug Administration (FDA) safety criteria. The independent panel evaluated a comprehensive dossier of characterization data and safety studies and concluded that Nephure is safe for use as a food ingredient.
Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.
Captozyme is pleased to announce that they have officially graduated from the University of Florida's Innovation Hub. In the fall of 2014 Captozyme found its home at the university's incubator for start-up companies in the technology and biotechnology fields. Now, a little over 2 years later, Captozyme graduates with 14 employees and a new office and lab space in north Gainesville.
Captozyme was recently honored in being one of the 20 companies chosen to present at the Florida Venture Forum out of more than 100 applicants. The Florida Venture Forum's mission is to connect emerging Florida-based companies with resources and capital nationwide.
The biotechnology company Captozyme is spearheading an innovative approach to nutrition to prevent the formation of painful kidney stones and other complications arising from the absorption of calcium oxalate from food. The company’s research efforts are led by Dr Qing-Shan Li, co-founder and CSO of the company.
Captozyme was one of 20 companies selected to participate in the 2017 Florida Venture Capital Conference, out of the more than 100 companies that applied to be a part of the weekend-long event.
Captozyme Inc., a biotechnology company based in Gainesville, FL, recently raised $3.4 million. Captozyme plans to invest this money into the manufacturing and launch of Nephure, an oxalate-degrading enzyme to facilitate a low-oxalate diet.
Since opening in 2010, the Innovation Hub has helped launch 61 companies that created 763 jobs and lured more than $50 million in private investment.